Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

NCT04321993 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

363

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Baricitinib (janus kinase inhibitor)
DRUG: Remdesivir (antiviral) + barictinib (janus kinase inhibitor)
DRUG: Remdesivir (antiviral)
DRUG: Tocilizumab (interleukin 6 inhibitor)

Sponsor

Lisa Barrett

Collaborators

[object Object]
[object Object]